Company Angling For Partnerships With Western Companies -- Simcere Pharma (SCR) of China, a company that bills itself as a maker of branded generic drugs for the domestic (Chinese) market, has filed to make its IPO and list on the NYSE. The company focuses on first-to-market generics, including an anti-stroke drug and an anti-cancer medication. The Simcere portfolio of drugs has high margins, because they treat serious diseases or are in high demand. More details...